Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer

Figure 1

Expression of PBK, PDZK1 and ANLN protein in breast cancer. A: Western blot analysis of PBK, PDZK1 and ANLN protein expression across a panel of 7 breast cancer cell lines of varying invasive capabilities. ANLN antibody specificity also validated by shRNA-mediated knockdown (data not shown). B: Validation of the PBK and PDZK1 antibodies by immunohistochemistry in a panel of FFPE breast cancer cell lines (x20 magnification). The T47D, MDA-MB-231 and Hs578T (i8) cell lines are specifically shown. Antibody positivity is indicated by the brown DAB staining. C: Representative cores of ANLN, PDZK1 and PBK protein expression from the TMAs graded on a scale from 0 to 3+ for protein staining intensity. Vertical red line represents the cut-off between low and high protein expression for each biomarker.

Back to article page